Gut Liver.  2014 Jan;8(1):109-112.

Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature

Affiliations
  • 1Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. mjchung@yuhs.ac
  • 2Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 3Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Abstract

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

Keyword

Hemolytic-uremic syndrome; Gemcitabine; Pancreatic neoplasms

MeSH Terms

Antimetabolites, Antineoplastic/*adverse effects
Deoxycytidine/adverse effects/*analogs & derivatives
Hemolytic-Uremic Syndrome/*chemically induced
Humans
Male
Middle Aged
Pancreatic Neoplasms/*drug therapy
Treatment Outcome
Antimetabolites, Antineoplastic
Deoxycytidine
Full Text Links
  • GNL
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr